Hodgkin disease risk: Role of genetic polymorphisms and gene-gene interactions in inflammation pathway genes

Molecular Carcinogenesis

Volumn 50, Issue 1, 2011, Pages 36-46

  Monroy, Claudia M ^a   Cortes, Andrea C ^a   Lopez, Mirtha S ^a   D'Amelio, Anthony M ^a   Etzel, Carol J ^a   Younes, Anas ^a   Strom, Sara S ^a   El Zein, Randa A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cytokine polymorphisms; Hodgkin disease; Inflammation genes

Indexed keywords

CYCLOOXYGENASE 2; I KAPPA B KINASE BETA; IMMUNOGLOBULIN E RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN RECEPTOR; INTERLEUKIN RECEPTOR 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; EPIGENETICS; FEMALE; GENE INTERACTION; GENETIC RISK; HODGKIN DISEASE; HUMAN; INFLAMMATION; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SCORING SYSTEM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; CYTOKINES; DNA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HODGKIN DISEASE; HUMANS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-18; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN-4; RISK FACTORS; YOUNG ADULT;

EID: 78650214156     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20688     Document Type: Article

References (50)

1. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009; 9: 15-27.
2. Cohen MC, Cohen S. Cytokine function: A study in biologic diversity. Am J Clin Pathol 1996; 105: 589-598.
3. Germano G, Allavena P, Mantovani A. Cytokines as a key component of cancer-related inflammation. Cytokine 2008; 43: 374-379.
4. Reyes-Gibby CC, Wu X, Spitz M, et al. Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol 2008; 9: 777-785.
5. Loktionov A. Common gene polymorphisms, cancer progression and prognosis. Cancer Lett 2004; 208: 1-33.
6. Mettler L, Salmassi A, Heyer M, Schmutzier A, Schollmeyer T, Jonat W. Perioperative levels of interleukin-1beta and interleukin-6 in women with breast cancer. Clin Exp Obstet Gynecol 2004; 31: 20-22.
7. Gao LB, Rao L, Wang YY, et al. The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis 2009; 30: 295-299.
8. Carpagnano GE, Spanevello A, Curci C, et al. IL-2, TNF-alpha, and leptin: Local versus systemic concentrations in NSCLC patients. Oncol Res 2007; 16: 375-381.
9. Hsia CY, Huo TI, Chiang SY, et al. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur J Surg Oncol 2007; 33: 208-212.
10. Bushley AW, Ferrell R, McDuffie K, et al. Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer. Gynecol Oncol 2004; 95: 672-679.
11. Brenner AV, Butler MA, Wang SS, et al. Single-nucleotide polymorphisms in selected cytokine genes and risk of adult glioma. Carcinogenesis 2007; 28: 2543-2547.
12. Diakowska D, Markocka-Maczka K, Grabowski K, Lewandowski A. Serum interleukin-12 and interleukin-18 levels in patients with esophageal squamous cell carcinoma. Exp Oncol 2006; 28: 319-322.
13. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Malecka-Panas E. Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci 2009; 54: 683-689.
14. Takeshi U, Sadar MD, Suzuki H, et al. Interleukin-4 in patients with prostate cancer. Anticancer Res 2005; 25: 4595-4598.
15. Mustea A, Braicu EI, Koensgen D, et al. Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: Results from a prospective pilot-study. Cytokine 2009; 45: 8-11.
16. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma: Correlation with phenotypic characteristics and prognosis. Cancer 2004; 101: 2727-2736.
17. Munro LR, Johnston PW, Marshall NA, et al. Polymorphisms in the interleukin-10 and interferon gamma genes in Hodgkin lymphoma. Leuk Lymphoma 2003; 44: 2083-2088.
18. Lech-Maranda E, Baseggio L, Bienvenu J, et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 2004; 103: 3529-3534.
19. Nieters A, Beckmann L, Deeg E, Becker N. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun 2006; 7: 615-624.
20. Fujii A, Ohshima K, Hamasaki M, et al. Differential expression of chemokines, chemokine receptors, cytokines and cytokine receptors in diffuse large B cell malignant lymphoma. Int J Oncol 2004; 24: 529-538.
21. Cerhan JR, Ansell SM, Fredericksen ZS, et al. Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood 2007; 110: 4455-4463.
22. Wang SS, Cerhan JR, Hartge P, et al. Common genetic variants in pro-inflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res 2006; 66: 9771-9780.
23. Rhein P, Scheid S, Ratei R, et al. Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterize leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemia. Leukemia 2007; 21: 897-905.
24. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1984; AC-19: 716-723.
25. Chernick MR. Bootstrap methods: A practitioner's guide. John Wiley & Sons; 1999. pp. 45-92.
26. Ritchie MD, Hahn LW, Roodi N, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001; 69: 138-147.
27. Breiman L, Friedman JN, Olsen RA. Stone CJ. Classification and regression trees. Monterey: Wadsworth and Brooks/Cole; 1984. pp. 15-50.
28. Clària J. Cyclooxygenase-2 biology. Curr Pharm Des 2003; 9: 2177-2190.
29. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: Progress and perspective. Cancer Lett 2004; 215: 1-20.
30. Hoeft B, Becker N, Deeg E, Beckmann L, Nieters A. Joint effect between regular use of non-steroidal anti-inflammatory drugs, variants in inflammatory genes and risk of lymphoma. Cancer Causes Control 2008; 19: 163-173.
31. Otto SP, Yong P. The evolution of gene duplicates. Adv Genet 2002; 46: 451-483.
32. Khripko OP, Sennikova NS, Lopatnikova JA, et al. Association of single nucleotide polymorphisms in the IL-18 gene with production of IL-18 protein by mononuclear cells from healthy donors. Mediators Inflamm 2008; 2: 1-6.
33. Park S, Cheon S, Cho D. The dual effects of interleukin-18 in tumor progression. Cell Mol Immunol 2007; 4: 329-335.
34. Taniguchi M, Nagaoka K, Kunikata T, et al. Characterization of anti-human interleukin-18 (IL-18)/interferon-gamma-inducing factor (IGIF) monoclonal antibodies and their application in the measurement of human IL-18 by ELISA. J Immunol Methods 1997; 206: 107-113.
35. Takubo T, Kumura T, Nakao T, et al. Comparative study on complete remission rate and overall survival in three groups classified based on the serum interleukin-18 level in non-Hodgkin's lymphoma patients. Acta Haematol 2000; 104: 220-222.
36. Lan Q, Zheng T, Rothman N, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006; 107: 4101-4108.
37. Schoof N, von Bonin F, Zeynalova S, et al. Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial. Ann Oncol 2009; 20: 1548-1554.
38. Habermann TM, Wang SS, Maurer MJ, et al. Host immune gene polymorphisms in combination with clinical and demographic factors predicts late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood 2008; 112: 2694-2702.
39. Skapenko A, Kalden JR, Lipsky PE, Schulze-Koops H. The IL-4 receptor alpha-chain-binding cytokines, IL-4 and IL-13, induce forkhead box P3-expressing CD25+CD4+ regulatory T cells from CD25-CD4+ precursors. J Immunol 2005; 175: 6107-6116.
40. Messi M, Giacchetto I, Nagata K, Lanzavecchia A, Natoli G, Sallusto F. Memory and flexibility of cytokine gene expression as separable properties of human T (H) 1 and T (H) 2 lymphocytes. Nat Immunol 2003; 4: 78-86.
41. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103: 1755-1762.
42. Herling M, Rassidakis GZ, Medeiros LJ, et al. Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: Associations with presenting features, serum interleukin 10 levels, and clinical outcome. Clin Cancer Res 2003; 9: 2114-2120.
43. Hohaus S, Giachelia M, Massini G, et al. Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. Leuk Res 2009; 6: 1352-1356.
44. Chang HD, Helbig C, Tykocinski L, et al. Expression of IL-10 in Th memory lymphocytes is conditional on IL-12 or IL-4, unless the IL-10 gene is imprinted by GATA-3. Eur J Immunol 2007; 37: 807-817.
45. Harizi H, Norbert G. Inhibition of IL-6, TNF-alpha, and cyclooxygenase-2 protein expression by prostaglandin E2-induced IL-10 in bone marrow-derived dendritic cells. Cell Immunol 2004; 228: 99-109.
46. Niiro H, Otsuka T, Ogami E, et al. MAP kinase pathways as a route for regulatory mechanisms of IL-10 and IL-4 which inhibit COX-2 expression in human monocytes. Biochem Biophys Res Commun 1998; 250: 200-205.
47. Pockaj BA, Basu GD, Pathangey LB, et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol 2004; 11: 328-339.
48. Shattuck-Brandt RL, Varilek GW, Radhika A, Yang F, Washington MK, DuBois RN. Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterology 2000; 118: 337-345.
49. Zhu J, Yamane H, Cote-Sierra J, Guo L, Paul WE. GATA-3 promotes Th2 responses through three different mechanisms: Induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res 2006; 16: 3-10.
50. Lee HJ, Takemoto N, Kurata H, et al. Gata-3 induces T helper cell type 2 (Th2) cytokine expression and chromatin remodeling in committed Th1 cells. J Exp Med 2000; 192: 105-116.